Community protocols on TRT describe: GHRP-2: 100-300 mcg subcutaneous, 2-3x daily GHRP-6: 100-300 mcg subcutaneous, 2-3x daily (dosed before meals to leverage the appetite increase) Pairing with CJC-1295 (no DAC) for amplified pulses Shorter cycles (8-12 weeks) due to desensitization risk at higher doses For the head-to-head comparison, see our GHRP-2 vs GHRP-6 analysis
Semaglutide works through GLP-1 alone, and tirzepatide combines GLP-1 with GIP, but neither touches glucagon
The resulting hyperglycemic conditions can in turn lead to chronic inflammation [2], leading to a myriad of complications such as diabetic nephropathy, polyneuropathy, and retinopathy [3, 4]
Low levels of B12 can lead to tiredness, weakness, poor concentration, and mood changes